This is a multicenter, open-label, single-arm, phase II clinical trial to evaluate the efficacy and safety of margetuximab in combination with tucatinib and capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.

Start Date15 May 2022

Sponsor / Collaborator

Medica Scientia Innovation Research SL

[+2]

CTR20200660 / SuspendedPhase 2/3

一项评价Margetuximab联合INCMGA00012和化疗、或联合MGD013和化疗在初治HER2阳性、转移性或局部晚期胃癌或胃食管结合部癌患者疗效的II/III期临床试验

[Translation] A Phase II/III clinical trial evaluating the efficacy of margetuximab in combination with INCMGA00012 and chemotherapy, or in combination with MGD013 and chemotherapy in patients with HER2-positive, metastatic or locally advanced gastric or gastroesophageal junction cancer who have never been treated

队列A：评估margetuximab＋INCMGA00012在人表皮生长因子受体2（HER2）免疫组织化学（IHC）3＋、并且IHC染色检验的PD-L1＋、排除微卫星不稳定（MSI）-高表达（MSI-H）的、未经治疗的局部晚期或转移性胃癌（GC）或胃食管结合部癌（GEJ）患者中的安全性和耐受性。评估margetuximab＋INCMGA00012在肿瘤缓解可评估人群（REP）中、通过中心影像以及研究者评估的客观缓解率（ORR）。队列B，第1部分：根据在主要肿瘤缓解可评估人群（PREP）中的安全性和ORR评估结果，不考虑PD-L1状态，选择在后续第2部分研究中将采用的margetuximab、化疗和包括CPI治疗的最佳联合治疗方案。队列B，第2部分：比较采用队列B，第1部分选择的margetuximab、化疗和包括CPI治疗的联合治疗方案与曲妥珠单抗联合化疗方案（对照组）在主要疗效人群（PEP）的总生存期（OS）

[Translation]

Cohort A: To evaluate the safety and tolerability of margetuximab + INCMGA00012 in patients with untreated locally advanced or metastatic gastric cancer (GC) or gastroesophageal junction cancer (GEJ) who are human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ and PD-L1+ by IHC staining, and exclude microsatellite instability (MSI)-high (MSI-H). To evaluate the objective response rate (ORR) of margetuximab + INCMGA00012 in the tumor response evaluable population (REP) by central imaging and investigator assessment. Cohort B, Part 1: Based on the safety and ORR assessment results in the primary tumor response evaluable population (PREP), regardless of PD-L1 status, select the best combination of margetuximab, chemotherapy, and CPI therapy to be used in the subsequent Part 2 study. Cohort B, Part 2: Comparison of overall survival (OS) in the primary efficacy population (PEP) between margetuximab, chemotherapy, and combination therapy including CPI therapy selected in Cohort B, Part 1 and trastuzumab plus chemotherapy (control group)

Start Date15 Dec 2020

Sponsor / Collaborator

Zai Lab (Shanghai) Co., Ltd.

CTR20200242 / CompletedPhase 1

一项评价Margetuximab联合化疗在HER2表达阳性经标准治疗失败的转移性乳腺癌患者中的药代动力学、安全性及耐受性的I期研究

[Translation] A Phase I Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Margetuximab Combined with Chemotherapy in Patients with HER2-positive Metastatic Breast Cancer Who Failed Standard Therapy

主要研究目的：评估Margetuximab联合化疗治疗中国HER2表达阳性的既往接受过抗HER2靶向治疗失败的转移性乳腺癌患者的药代动力学（PK）特征。次要研究目的：评估margetuximab联合化疗治疗HER2表达阳性的既往接受过抗HER2靶向治疗失败的转移性乳腺癌的安全性及耐受性评价针对margetuximab的抗药物抗体（ADA）及其对PK、疗效和安全性的影响

[Translation]

The primary study objective is to evaluate the pharmacokinetic (PK) characteristics of margetuximab combined with chemotherapy in the treatment of Chinese patients with HER2-positive metastatic breast cancer who have previously failed anti-HER2 targeted therapy. The secondary study objectives are to evaluate the safety and tolerability of margetuximab combined with chemotherapy in the treatment of HER2-positive metastatic breast cancer who have previously failed anti-HER2 targeted therapy. To evaluate anti-drug antibodies (ADA) against margetuximab and their effects on PK, efficacy and safety.

Start Date28 Aug 2020

Sponsor / Collaborator

Zai Lab (Shanghai) Co., Ltd.

100 Clinical Results associated with Margetuximab

100 Translational Medicine associated with Margetuximab

100 Patents (Medical) associated with Margetuximab

Literatures (Medical) associated with Margetuximab

01 May 2024·Anti-Cancer Agents in Medicinal Chemistry

An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021)

Review

Author: Vishakha, S ; Kurmi, Balak Das ; Patel, Preeti ; Navneesh, N ; Jain, Ankit ; Gupta, Ghanshyam Das ; Verma, Sant Kumar

Abstract:New drugs being established in the market every year produce specified structures for selective biological targeting. With medicinal insights into molecular recognition, these begot molecules open new rooms for designing potential new drug molecules. In this review, we report the compilation and analysis of a total of 56 drugs including 33 organic small molecules (Mobocertinib, Infigratinib, Sotorasib, Trilaciclib, Umbralisib, Tepotinib, Relugolix, Pralsetinib, Decitabine, Ripretinib, Selpercatinib, Capmatinib, Pemigatinib, Tucatinib, Selumetinib, Tazemetostat, Avapritinib, Zanubrutinib, Entrectinib, Pexidartinib, Darolutamide, Selinexor, Alpelisib, Erdafitinib, Gilteritinib, Larotrectinib, Glasdegib, Lorlatinib, Talazoparib, Dacomitinib, Duvelisib, Ivosidenib, Apalutamide), 6 metal complexes (Edotreotide Gallium Ga-68, fluoroestradiol F-18, Cu 64 dotatate, Gallium 68 PSMA-11, Piflufolastat F-18, 177Lu (lutetium)), 16 macromolecules as monoclonal antibody conjugates (Brentuximabvedotin, Amivantamab-vmjw, Loncastuximabtesirine, Dostarlimab, Margetuximab, Naxitamab, Belantamabmafodotin, Tafasitamab, Inebilizumab, SacituzumabGovitecan, Isatuximab, Trastuzumab, Enfortumabvedotin, Polatuzumab, Cemiplimab, Mogamulizumab) and 1 peptide enzyme (Erwiniachrysanthemi-derived asparaginase) approved by the U.S. FDA between 2018 to 2021. These drugs act as anticancer agents against various cancer types, especially non-small cell lung, lymphoma, breast, prostate, multiple myeloma, neuroendocrine tumor, cervical, bladder, cholangiocarcinoma, myeloid leukemia, gastrointestinal, neuroblastoma, thyroid, epithelioid and cutaneous squamous cell carcinoma. The review comprises the key structural features, approval times, target selectivity, mechanisms of action, therapeutic indication, formulations, and possible synthetic approaches of these approved drugs. These crucial details will benefit the scientific community for futuristic new developments in this arena.

12 Jan 2024·Cancer Discovery

Tebotelimab Is Safe and Effective Across Multiple Cancer Types

Article

AbstractThe PD-1 × LAG-3 bispecific molecule tebotelimab is safe as a monotherapy and in combination with margetuximab.

01 Jan 2024·Clinics and Research in Hepatology and Gastroenterology

New developments and standard of care in the management of advanced gastric cancer

Review

Author: Broudin, Chloé ; Rasola, Cosimo ; Palle, Juliette ; Zaanan, Aziz ; Afrăsânie, Vlad-Adrian ; Depotte, Léonard ; Mariani, Antoine

Advanced gastric adenocarcinoma is a common disease with a poor prognosis whose treatment has for decades been based on cytotoxic chemotherapy, including platinum salts in first-line, and taxane or irinotecan in second or later line. Recent years have seen the emergence of new drugs that have improved patient survival, such as trastuzumab in first-line for HER2-positive tumors, ramucirumab alone or in combination with paclitaxel in second-line, and trifluridine-tipiracil beyond the second-line treatment. More recently, two monoclonal antibodies have demonstrated their efficacy in combination with oxaliplatin-based first-line chemotherapy, nivolumab (anti-PD1) for PD-L1 CPS ≥5 tumors, and zolbetuximab for tumors overexpressing Claudin 18.2. In addition, regorafenib has been also showed effective in phase 3 trial for heavily pretreated patients. Based on phase 2 studies, trastuzumab-deruxtecan was approved in 2022 by the EMA for HER2-positive pretreated patients. This agent is currently evaluated in phase 3 study (DESTINY-Gastric04 trial), as are several other anti-HER2 (zanidatamab, margetuximab, tucatinib), immune checkpoint inhibitors, or targeted therapies (anti-FGFR2b).

News (Medical) associated with Margetuximab

30 Oct 2024

·www.globenewswire.com

MacroGenics Announces Leadership Transition

Scott Koenig, M.D., Ph.D., to step down as President and CEOBoard to initiate search process to identify new CEO ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that Scott Koenig, M.D., Ph.D., intends to step down as President and Chief Executive Officer early next year. The Company’s Board of Directors has retained Heidrick & Struggles to lead a search process to identify its next Chief Executive Officer and has established a special committee of the Board to oversee the transition process. William Heiden, Chairman of the Board of Directors said, “Scott was a co-founder of MacroGenics twenty-four years ago and the Company has achieved many milestones under his leadership – including several partnered or company-owned FDA approved monoclonal antibody therapeutics developed by the company. On behalf of the Board, I want to thank Scott for his incredible dedication to the Company’s mission of discovering and developing novel therapeutics to improve patient care.” Mr. Heiden continued, “Today, MacroGenics has several innovative antibody-based therapeutics in development for the treatment of cancer, as well as significant alliances with leading pharmaceutical and biotechnology companies to develop and commercialize novel therapeutics. The Company today has a broad portfolio of promising assets and a strong balance sheet, and the Board and Scott agreed that this is the right time to transition to our next phase of leadership. We look forward to continuing to benefit from his perspectives as an advisor and shareholder.” “I am proud of our many achievements since our founding in 2000, in which we built a fully integrated, science-focused biotechnology company and have been successful in discovering, developing, manufacturing, and commercializing novel immunotherapeutics derived from our proprietary Fc-engineered antibody, bi-specific DART molecule, and antibody drug conjugate (ADC) technologies,” said Dr. Koenig. “Since the company’s IPO in 2013, we were able to fund a significant part of the development portfolio through the achievement of over $1 billion of non-dilutive capital via partnerships. Thanks to the incredible passion and dedication of the people at MacroGenics, three novel therapeutics from our pipeline advanced to approval, including MARGENZA® and ZYNYZ® to treat patients with cancer, and TZIELD® for individuals with early-stage Type 1 diabetes, and we have advanced a rich portfolio of clinical and preclinical molecules in development. I am confident that MacroGenics is well positioned in its current mission to address the significant unmet medical needs of patients with cancer. I look forward to continuing to support the Company in its work to achieve its key strategic objectives and create value for all our stakeholders.” About MacroGenics, Inc. MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo and MARGENZA are trademarks or registered trademarks of MacroGenics, Inc. Cautionary Note on Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for MacroGenics (“Company”), including statements about the Company’s strategy, future operations, clinical development of and regulatory plans for the Company’s therapeutic candidates, expected timing of the release of final safety and efficacy data, including mature median rPFS and other statements containing the words “subject to”, "believe", “anticipate”, “plan”, “expect”, “intend”, “estimate”, “potential,” “project”, “may”, “will”, “should”, “would”, “could”, “can”, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks that TZIELD, vobramitamab duocarmazine, lorigerlimab, ZYNYZ, MARGENZA or any other product candidate’s revenue, expenses and costs may not be as expected, risks relating to TZIELD, vobramitamab duocarmazine, lorigerlimab, ZYNYZ, MARGENZA or any other product candidate’s market acceptance, competition, reimbursement and regulatory actions; future data updates, especially timing and results of mature median radiographic progression-free survival, other efficacy and safety data with respect to vobramitamab duocarmazine; our ability to provide manufacturing services to our customers; the uncertainties inherent in the initiation and enrollment of future clinical trials; the availability of financing to fund the internal development of our product candidates; expectations of expanding ongoing clinical trials; availability and timing of data from ongoing clinical trials; expectations for the timing and steps required in the regulatory review process; expectations for regulatory approvals; expectations of future milestone payments; the impact of competitive products; our ability to enter into agreements with strategic partners and other matters that could affect the availability or commercial potential of the Company's product candidates; business, economic or political disruptions due to catastrophes or other events, including natural disasters, terrorist attacks, civil unrest and actual or threatened armed conflict, or public health crises; costs of litigation and the failure to successfully defend lawsuits and other claims against us; and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. ###

Executive ChangeIPOADC

23 Oct 2024

·www.biopharmadive.com

Merck acquires cancer drug startup; Elevidys ex-US sales rise

Today, a brief rundown of news from Merck & Co. and Roche, as well as updates from Sangamo Therapeutics, UCB and Catalent that you may have missed.Merck & Co. will pay $30 million upfront to acquire Modifi Biosciences, a Yale University spinout developing small molecule drugs for cancer. Founded in 2021, Modifi focuses on DNA repair defects in cancer cells, specifically one repair protein known as MGMT for short. Shareholders in Modifi could receive up to $1.3 billion in additional payments if certain, unspecified milestones are met. Ned PagliaruloSales of Sarepta Therapeutics Duchenne muscular dystrophy gene therapy Elevidysoutside of the U.S. reached 137 million Swiss francs, or about $156 million, over the first nine months of the year, the companys international partner Roche said Wednesday. Those sales came from five ex-U.S. countries where Elevidys is also approved. A decision is expected in the EU next year, and Roche has submitted applications in several other countries. The Swiss group cited Elevidys, along with multiple sclerosis shot Ocrevus, as one of its key growth drivers in neurology, which showed a sales increase of 14% to 7 billion francs over the same period in 2023. Jonathan GardnerShares in Sangamo Therapeutics rose Tuesday after the company said it has secured agreement from the Food and Drug Administration on a path to filing its experimental Fabry disease treatment for approval. According to the biotechnology company, regulators agreed that a measure of kidney function could be used as a surrogate endpoint to ask it for accelerated clearance of the gene therapy, dubbed isaralgagene civaparvovec or ST-920. Sangamo expects to have the necessary data by the first half of next year, setting up a submission in the latter half of 2025 some three years earlier than the company had been planning. Ned PagliaruloRoche has returned to UCB rights to an experimental Alzheimers medicine UCB had licensed to the Swiss pharmaceutical company in 2020. The company confirmed Roches termination of the collaboration in a statement Tuesday announcing the planned presentation of Phase 2 study results for the drug, bepranemab, at an upcoming medical meeting. Tested in people with prodromal or mild Alzheimers, bepranemab is designed to target a protein known as tau in the brain. Ned PagliaruloMacroGenics, a developer of antibody medicines for cancer, on Tuesday said it sold rights to its breast cancer drug Margenza to privately held TerSera Therapeutics for $40 million. MacroGenics could receive up to $35 million more if certain sales milestones are met under the deal, which is expected to close in the fourth quarter. Margenza was approved in 2020 together with chemotherapy for adults with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Delilah AlvaradoCell therapy developer AvenCell Therapeutics raised $112 million in a Series B financing led by investor Novo Holdings. The funding will fund development of the companys switchable CAR-T medicines, which it claims could be safer and more effective than current options. F-Prime Capital, founding investor Blackstone Life Sciences and three other venture firms participated in the round. Delilah AlvaradoCatalent, the contract development and manufacturing organization being acquired by Novo Holdings, issued a letter Monday to its customers aimed at reassuring them it will continue to fulfill its commitments after the transaction closes. Novo Holdings, which is the parent company of drugmaker Novo Nordisk, is taking Catalent private through a $16.5 billion acquisition. Novo Nordisk is then buying three large Catalent plants in a separate $11 billion agreement. Alessandro Maselli, Catalents current CEO, will stay on in his role, the letter said. Ned Pagliarulo '

AcquisitionDrug ApprovalGene TherapyPhase 2

22 Oct 2024

·pipelinereview.com

MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®

ROCKVILLE, MD & DEERFIELD, IL, USA I October 22, 2024 I MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, and TerSera Therapeutics LLC, a privately-held biopharmaceutical company with a focus in oncology and non-opioid pain management, announced today that they have entered into an agreement in which TerSera will acquire global rights to MARGENZA® (margetuximab-cmkb). MARGENZA was approved by the U.S. Food and Drug Administration (FDA) in December 2020 in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. The approval was based on results from the pivotal Phase 3 head-to-head clinical trial (SOPHIA) evaluating the safety and efficacy of MARGENZA vs. Herceptin® (trastuzumab), both combined with chemotherapy. Pursuant to the terms of the agreement, TerSera will pay MacroGenics $40 million at closing. MacroGenics may receive additional sales milestone payments of up to an aggregate of $35 million. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions. “This transaction will enable us to focus our efforts on advancing our pipeline of novel and differentiated oncology product candidates,” said Scott Koenig, M.D., Ph.D., President and Chief Executive Officer of MacroGenics. “We believe TerSera’s established and complementary U.S. commercial infrastructure has the potential to broaden patient access to MARGENZA.” “MARGENZA is an important treatment option for patients with metastatic HER2+ breast cancer,” said Edward Donovan, Chief Executive Officer of TerSera. “We are very excited to add MARGENZA to our existing oncology portfolio, deepening our commitment to the treatment of patients with breast cancer.” IMPORTANT SAFETY INFORMATION BOXED WARNING: LEFT VENTRICULAR DYSFUNCTION AND EMBRYO-FETAL TOXICITY WARNINGS & PRECAUTIONS: Left Ventricular Dysfunction Embryo-Fetal Toxicity Infusion-Related Reactions (IRRs) MOST COMMON ADVERSE REACTIONS: The most common adverse drug reactions (>10%) with MARGENZA in combination with chemotherapy are fatigue/asthenia (57%), nausea (33%), diarrhea (25%), vomiting (21%), constipation (19%), headache (19%), pyrexia (19%), alopecia (18%), abdominal pain (17%), peripheral neuropathy (16%), arthralgia/myalgia (14%), cough (14%), decreased appetite (14%), dyspnea (13%), infusion-related reactions (13%), palmar-plantar erythrodysesthesia (13%), and extremity pain (11%). You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to MacroGenics at (844)-MED-MGNX (844-633-6469). INDICATION MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. Please see full Prescribing Information , including Boxed Warning. About HER2-positive Breast Cancer Human epidermal growth factor receptor 2 (HER2) is a protein found on the surface of some cancer cells that promotes growth and is associated with aggressive disease and poor prognosis. Approximately 15-20% of breast cancer cases are HER2-positive. Monoclonal antibodies targeting HER2 have greatly improved outcomes; however, a significant number of patients progress to later lines of therapy. Effective treatments for metastatic HER2-positive breast cancer continue to remain an unmet need. About MARGENZA MARGENZA (margetuximab-cmkb) is an Fc-engineered, monoclonal antibody that targets the HER2 oncoprotein. HER2 is expressed by tumor cells in breast, gastroesophageal and other solid tumors. Similar to trastuzumab, margetuximab-cmkb inhibits tumor cell proliferation, reduces shedding of the HER2 extracellular domain and mediates antibody-dependent cellular cytotoxicity (ADCC). However, through MacroGenics’ Fc Optimization technology, margetuximab-cmkb has been engineered to enhance the engagement of the immune system. In vitro, the modified Fc region of margetuximab-cmkb increases binding to the activating Fc receptor FCGR3A (CD16A) and decreases binding to inhibitor Fc receptor FCGR2B (CD32B). These changes lead to greater in vitro ADCC and NK cell activation. The clinical significance of in vitro data is unknown. About MacroGenics, Inc. MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics’ technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company’s website at www.macrogenics.com . About TerSera Therapeutics TerSera Therapeutics is a biopharmaceutical company with a focus in oncology and non-opioid pain management. Founded in 2016, TerSera is building new cornerstones of care through its portfolio of unique therapeutics, amplifying their ability to deliver meaningful outcomes for patients. TerSera has been recognized as a 2024 Healthcare Top Workplace. For additional information, please visit tersera .com and follow us on LinkedIn . SOURCE: MacroGenics

License out/inDrug ApprovalPhase 3Clinical ResultADC

100 Deals associated with Margetuximab

External Link

KEGG	Wiki	ATC	Drug Bank
D10446	Margetuximab	L01XC	DB14967

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HER2 Positive Breast Cancer	US	MacroGenics, Inc.	16 Dec 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HER2 Positive Breast Cancer	NDA/BLA	CN	Zai Lab (Shanghai) Co., Ltd.	06 Jan 2022
Neoplasm Metastasis	Discovery	NL	MacroGenics, Inc.	24 Aug 2015
Neoplasm Metastasis	Discovery	IL	MacroGenics, Inc.	24 Aug 2015
Neoplasm Metastasis	Discovery	IT	MacroGenics, Inc.	24 Aug 2015
Neoplasm Metastasis	Discovery	PT	MacroGenics, Inc.	24 Aug 2015
Neoplasm Metastasis	Discovery	FR	MacroGenics, Inc.	24 Aug 2015
Neoplasm Metastasis	Discovery	US	MacroGenics, Inc.	24 Aug 2015
Neoplasm Metastasis	Discovery	FI	MacroGenics, Inc.	24 Aug 2015
Neoplasm Metastasis	Discovery	GB	MacroGenics, Inc.	24 Aug 2015
Neoplasm Metastasis	Discovery	ES	MacroGenics, Inc.	24 Aug 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02689284 (CP-MGAH22-05, Pubmed)	Phase 1/2	HER2 Positive Gastroesophageal Adenocarcinoma	86	Margetuximab and Pembrolizumab combination therapy	(gpzhmzjygp) = pyunfmiafa ftbtmkuqqu (phuzudivud )	-	25 Apr 2023
NCT02492711 (SOPHIA, CTgov)	Phase 3	Neoplasm Metastasis \| Metastatic human epidermal growth factor 2 positive carcinoma of breast	624	Physician's choice of chemotherapy.+Margetuximab (Margetuximab Plus Chemotherapy)	uxyvwhumyt(yaygpiibth) = wnttjimymi imnfcxigyq (ifmcfgpgik, yhlsbmlhpp - mdfnhjbutz) View more	-	23 Nov 2022
				Trastuzumab (Trastuzumab Plus Chemotherapy)	uxyvwhumyt(yaygpiibth) = nylvgglvys imnfcxigyq (ifmcfgpgik, izejzmotuq - flloydpwkj) View more
SOPHIA (NEWS) Manual	Not Applicable	HER2 Positive Breast Cancer HER2 positive	-	Chemotherapy+Margetuximab	(nfxjhsbfnb) = wuxwlwidfa eawswjnwus (tecxjsnuor ) View more	Superior	09 Nov 2022
				Chemotherapy+Trastuzumab	(nfxjhsbfnb) = ekqfanrnto eawswjnwus (tecxjsnuor ) View more
NCT02492711 (SOPHIA, Pubmed) Manual	Phase 3	Advanced HER2-Positive Breast Carcinoma HER2 Positive	536	Chemotherapy+Margetuximab	(jcbgtygnfm) = cfqlvekdmg rmlznksjft (obuqoiovac, 18.89 - 25.07)	Non-superior	04 Nov 2022
				Chemotherapy+Trastuzumab	(jcbgtygnfm) = mffetnxesr rmlznksjft (obuqoiovac, 18.69 - 24.18)
NCT04262804 (Pubmed)	Phase 2	Metastatic human epidermal growth factor 2 positive carcinoma of breast Last line HER2-positive	123	Margetuximab plus chemotherapy	dyicmbuybq(errkknkwnt) = qamzdffspe dwlgecsukg (jpuvublqoq ) View more	Positive	01 Oct 2022
				Trastuzumab plus chemotherapy	dyicmbuybq(errkknkwnt) = ynneyxpycf dwlgecsukg (jpuvublqoq ) View more
NCT04082364 (MAHOGANY, Pubmed) Manual	Phase 2/3	HER2 Positive Gastroesophageal Adenocarcinoma First line HER2 Positive \| PD-L1 Positive	43	Margetuximab+Retifanlimab	kgngxrvkss(jdzuceunst) = adpkysiakf irdegtrxek (jnfylrermp ) View more	Positive	24 Aug 2022
NCT02689284 (CP-MGAH22-05, CTgov)	Phase 1/2	Esophageal Carcinoma \| Metastatic HER2 positive gastroesophageal junction cancer \| Stomach Cancer	95	Margetuximab+Pembrolizumab (Margetuximab (10 mg/kg) Plus Pembrolizumab (200 mg))	dduaorkeyn(nvccamzblp) = bnizzsabiq ukqclesfms (zhlphdnegi, tkwrzfiflu - qmncvjenkg) View more	-	04 Aug 2022
				Margetuximab+Pembrolizumab (Margetuximab (15 mg/kg) Plus Pembrolizumab (200 mg))	dduaorkeyn(nvccamzblp) = bjlwagwjmz ukqclesfms (zhlphdnegi, ubrgsjlxmd - zibunyfckl) View more
ASCO2022	Phase 3	Advanced breast cancer	-	Margetuximab	(dlqfuexxgq) = these therapies are generally well tolerated with manageable side effects as listed in the table. ijvnchslbi (vkoitbdqwd ) View more	Positive	02 Jun 2022
				Trastuzumab
NCT04082364 (ESMO_GI2021)	Phase 2/3	Metastatic HER2 positive gastroesophageal junction cancer First line HER2+ \| PD-L1+ \| microsatellite instability	-	Margetuximab+Retifanlimab	(wrwmuovvur) = kuvcsexagx ljmketqtrk (blufsfeame )	Positive	03 Jul 2021
NCT02492711 (SOPHIA, Pubmed \| JAMA Oncol)	Phase 3	HER2 Positive Breast Cancer	536	Margetuximab	(pnnvswkjqh) = vtuoskxwpz hqfqbagimy (fqdhzgumvk ) View more	Positive	22 Jan 2021
				Trastuzumab	(pnnvswkjqh) = flqmwpwxoo hqfqbagimy (fqdhzgumvk ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis